Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the study is to investigate sleep apnea, circulation and metabolism in acromegaly before and after surgery and/or medical treatment.
Acromegaly is a rare disease caused by a growth hormone (GH) producing pituitary adenoma. Surgery is primary treatment, whereas medical treatment with a somatostatin analogue (SA), which suppresses GH secretion and reduces tumour size, is used when surgery is insufficient or unfeasible. Acromegaly is associated with metabolic abnormalities which contributes to an increased morbidity and mortality if left untreated. To which extend these abnormalities reverses after treatment, and if treatment modality influences the outcome, remain elusive. The aim of the study is to investigate sleep apnea, circulation and metabolism in acromegaly before and after surgery and/or medical treatment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Sleep apnea | ApneaLinkAir: respiratory effort, puls, oxygen saturation, nasal flow and snoring | At baseline (time of diagnosis) and at an average of 1 years treatment |
| Circulation | Sphygmocor: central arterial pressure and pulse wave velocity | At baseline (time of diagnosis) and at an average of 1 years treatment |
| Bone metabolism | HRpQCT scan | At baseline (time of diagnosis) and at an average of 1 years treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Heartfunction | Echocardiography | At baseline (time of diagnosis) and at an average of 1 years treatment |
| Substrate metabolism; signaling proteins | Western blotting |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- Pregnancy
Not provided
Not provided
Not provided
Newly diagnosed acromegalic patients
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Mai C Arlien-Søborg, MD | Contact | +45 23837420 | mas@clin.au.dk | |
| Jens Otto L Jørgensen, Professor | Contact | +45 24800664 | joj@clin.au.dk |
| Name | Affiliation | Role |
|---|---|---|
| Jens Otto L Jørgensen, Porfessor | Aarhus University Hospital, Department of internal medicine and endocrinology | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Aarhus University Hospital, Department of internal medicine and endocrinologi | Recruiting | Aarhus | 8000 | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41701620 | Derived | Baek A, Christiansen Arlien-Soborg M, Pedersen AKN, Dal J, Madsen MA, Hogild ML, Berryman D, Kopchick JJ, Pedersen SB, Bjerre M, Lebeck J, Jessen N, Jorgensen JOL. Growth hormone causes reversible fibrosis in muscle and fat: a study in patients with acromegaly. Eur J Endocrinol. 2026 Mar 4;194(3):299-306. doi: 10.1093/ejendo/lvag032. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000172 | Acromegaly |
| D012891 | Sleep Apnea Syndromes |
| D002318 | Cardiovascular Diseases |
| D001847 | Bone Diseases |
| ID | Term |
|---|---|
| D001849 | Bone Diseases, Endocrine |
| D009140 | Musculoskeletal Diseases |
| D006964 | Hyperpituitarism |
| D010900 | Pituitary Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood samples and tissue will be kept in a locked freezer thorughout the study period
| At baseline (time of diagnosis) and at an average of 1 years treatment |
| Substrate metabolism; gene targets | qPCR | At baseline (time of diagnosis) and at an average of 1 years treatment |
| Energy expenditure | Indirect calorimetry | At baseline (time of diagnosis) and at an average of 1 years treatment |
| Body composition | DXA scan | At baseline (time of diagnosis) and at an average of 1 years treatment |
| Physical activity | Sensoriband | At baseline (time of diagnosis) and at an average of 1 years treatment |
| D007027 |
| Hypothalamic Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D004700 | Endocrine System Diseases |
| D001049 | Apnea |
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |